Table S3.
Current treatment by CAT score domain in Europe
| Overall (N=1,242) | 0–9 (n=138) | 10–19 (n=405) | 20–29 (n=512) | 30–40 (n=187) | |
|---|---|---|---|---|---|
| Current treatment, n (%) | |||||
| Missing, n | 2 | 1 | 0 | 1 | 0 |
| Short-acting therapy | |||||
| SABA, SAMA, SABA/SAMA alone | 68 (5.5) | 19 (13.9) | 21 (5.2) | 23 (4.5) | 5 (2.7) |
| Maintenance therapies | |||||
| Bronchodilator monotherapy | |||||
| LAMA alone | 236 (19.0) | 45 (32.9) | 112 (27.7) | 69 (13.5) | 10 (5.4) |
| LABA alone | 73 (5.9) | 16 (11.7) | 26 (6.4) | 25 (4.9) | 6 (3.2) |
| Bronchodilator dual therapy | |||||
| LABA+LAMA | 123 (9.9) | 15 (11.0) | 38 (9.4) | 55 (10.8) | 15 (8.0) |
| Triple therapya | |||||
| ICS/LABA+LAMA | 385 (31.1) | 18 (13.1) | 92 (22.7) | 181 (35.4) | 94 (50.3) |
| LAMA+LABA+ICS | 27 (2.2) | 2 (1.5) | 9 (2.2) | 11 (2.2) | 5 (2.7) |
| ICS-based therapies not including dual LAMA+LABA component | |||||
| ICS alone | 21 (1.7) | 2 (1.5) | 9 (2.2) | 8 (1.6) | 2 (1.1) |
| ICS/LABA alone | 194 (15.7) | 15 (11.0) | 67 (16.5) | 86 (16.8) | 26 (13.9) |
| ICS+LAMA | 17 (1.4) | 1 (0.7) | 6 (1.5) | 4 (0.8) | 6 (3.2) |
| ICS+LABA | 10 (0.8) | 1 (0.7) | 2 (0.5) | 3 (0.6) | 4 (2.1) |
| ICS/LABA+LABA | 20 (1.6) | 2 (1.5) | 8 (1.9) | 9 (1.8) | 1 (0.5) |
| ICS/LABA+LTRA | 3 (0.2) | 0 | 1 (0.3) | 2 (0.4) | 0 |
| ICS/LABA+xanthines | 9 (0.7) | 1 (0.7) | 1 (0.3) | 6 (1.2) | 1 (0.5) |
| ICS/LABA+ICS | 0 | 0 | 0 | 0 | 0 |
| ICS/LABA+ICS+LTRA | 0 | 0 | 0 | 0 | 0 |
| ICS/LABA+ICS+xanthines | 0 | 0 | 0 | 0 | 0 |
| ICS+xanthines | 1 (0.1) | 0 | 1 (0.3) | 0 | 0 |
| ICS+LTRA | 0 | 0 | 0 | 0 | 0 |
| Other maintenance therapy | |||||
| LTRA alone | 1 (0.1) | 0 | 1 (0.3) | 0 | 0 |
| Xanthines alone | 4 (0.3) | 0 | 0 | 4 (0.8) | 0 |
| LABA+xanthines | 1 (0.1) | 0 | 0 | 1 (0.2) | 0 |
| ICS/LABA+LABA+LAMA | 9 (0.7) | 0 | 2 (0.5) | 6 (1.2) | 1 (0.5) |
| ICS/LABA+ICS+LAMA | 3 (0.2) | 0 | 0 | 1 (0.2) | 2 (1.1) |
| Other | 35 (2.8) | 0 | 9 (2.2) | 17 (3.3) | 9 (4.8) |
Note:
a
Triple therapy defined as a single LABA, a single LAMA and a single ICS therapy only.
Abbreviations: CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; LTRA, leukotriene receptor antagonist; SABA, short-acting β2-agonist; SAMA, short-acting muscarinic antagonist.